{
  "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "docSlug": "5062b9a9257606648ea145bccd66e04d",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 41,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a chronological structure to demonstrate operational momentum.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/5",
  "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "deckJsonHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json",
  "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.205
      },
      "kind": "callout",
      "text": "Resource-efficient execution and value creation across an expanding portfolio of wholly-owned programs",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83b165c0-7f65-47b5-b00b-ca96054606ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.06,
        "y": 0.36
      },
      "kind": "list",
      "text": "2021: EMERGENCE FROM STEALTH. Disclosed parallel lead programs (ROS1+ and ALK+ NSCLC). Presented preclinical profiles. Nasdaq listed: NUVL.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "448f7330-e386-449d-99d3-c5f6c7589e7f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.36,
        "y": 0.36
      },
      "kind": "list",
      "text": "2022: FIRST CLINICAL PROOF-OF-CONCEPT. Initiated two global Phase 1/2 studies. Demonstrated clinical proof-of-concept for ROS1 program. Disclosed third novel program (HER2 NSCLC).",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d7d3ad3-d82e-4f73-b10e-cb354f8cb46c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.66,
        "y": 0.36
      },
      "kind": "list",
      "text": "2023: SECOND PROOF-OF-CONCEPT & FIRST PIVOTAL STUDY. Demonstrated clinical proof-of-concept for ALK program. Initiated ARROS-1 Phase 2 with registrational intent. Advanced HER2 program towards IND.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa24ae58-5632-43b9-9c60-2a60405d147c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.15,
        "y": 0.79
      },
      "kind": "paragraph",
      "text": "Ended 2023 with approximately $719.9M* in cash, cash equivalents and marketable securities (unaudited), with potential to deliver multiple transformative catalysts within cash runway window into 2027",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5356373c-8eb2-40e4-a16c-9c279bb6dcb9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "* Preliminary, unaudited estimate only as of the date of this presentation; subject to change following completion of year-end closing procedures; does not present all information necessary for an understanding of financial position as of December 31, 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4adfddb-bb2d-4a0d-904f-c549625bdfd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.36,
        "x": 0.32,
        "y": 0.1
      },
      "kind": "title",
      "text": "Track Record of Success",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a80a73e-9785-46d1-a23f-535fb416582c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "e1853ad4-e906-4a3f-8c0a-0d43195a4239",
      "evidence": "Chronological presentation of milestones from 2021-2023",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}